VB Spine Secures FDA Breakthrough Status for Scoliosis Progression Blood Test
Event summary
- VB Spine's ScolimiR-3D blood test received FDA Breakthrough Device Designation on September 29, 2026.
- The test predicts scoliosis progression risk using six microRNAs with 100% sensitivity and specificity in validation studies.
- ScolimiR-3D aims to shift scoliosis management from reactive to proactive treatment planning.
- VB Spine is the largest privately-held spine company, led by the Viscogliosi brothers.
The big picture
VB Spine's FDA designation marks a potential inflection point in scoliosis care, shifting from reactive bracing/surgery to data-driven risk stratification. The Breakthrough Device Program prioritizes technologies addressing unmet needs in debilitating conditions, positioning ScolimiR-3D for expedited development. As the largest privately-held spine company, VB Spine leverages this advantage to scale diagnostic innovation across its global distribution network.
What we're watching
- Clinical Adoption
- How quickly physicians integrate ScolimiR-3D into scoliosis management protocols.
- Regulatory Pathway
- Whether the Breakthrough Designation accelerates ScolimiR-3D's path to full FDA approval.
- Market Differentiation
- The pace at which VB Spine can establish ScolimiR-3D as the standard for scoliosis risk assessment.
Related topics